bpV(HOpic), PTP and PTEN inhibitor (ab144214)

Overview

  • Product name

    bpV(HOpic), PTP and PTEN inhibitor
  • Description

    PTP and PTEN inhibitor
  • Biological description

    Inhibits PTP (IC50 = 4-25 µM) and PTEN (IC50 = 14 nM). Insulin mimetic. Enhances PI3K/Akt signaling and possibly prevents myocardium from ischemia-reperfusion injury. Active in vitro.

    See similar compound
  • Purity

    > 95%
  • General notes

    This product is not stable in water; immediately upon dissolution decomposition starts to occur. Decomposition in dry DMSO has also been observed but at a slower rate.

  • Chemical structure

    Chemical Structure

Properties

  • Chemical name

    Dipotassium bisperoxo(5-hydroxypyridine-2-carboxyl)oxovanadate (V)
  • Molecular weight

    347.24
  • Molecular formula

    C6H4K2NO8V
  • Storage instructions

    Store at -20°C. It is important to note that this product is reported to be light sensitive. Store In the Dark. Store under desiccating conditions.
  • Solubility overview

    Soluble in DMSO
  • Handling

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

  • Source

    Synthetic

References

This product has been referenced in:

  • Dimchev GA  et al. Phospho-tyrosine phosphatase inhibitor Bpv(Hopic) enhances C2C12 myoblast migration in vitro. Requirement of PI3K/AKT and MAPK/ERK pathways. J Muscle Res Cell Motil 34:125-36 (2013). Read more (PubMed: 23553034) »
  • Keyes KT  et al. Pharmacological inhibition of PTEN limits myocardial infarct size and improves left ventricular function postinfarction. Am J Physiol Heart Circ Physiol 298:H1198-208 (2010). Read more (PubMed: 20097771) »
  • Schmid AC  et al. Bisperoxovanadium compounds are potent PTEN inhibitors. FEBS Lett 566:35-8 (2004). Read more (PubMed: 15147864) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab144214.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up